Institution
Saint Louis University
Education•St Louis, Missouri, United States•
About: Saint Louis University is a education organization based out in St Louis, Missouri, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 18927 authors who have published 34895 publications receiving 1267475 citations. The organization is also known as: SLU & St. Louis University.
Topics: Population, Poison control, Health care, Transplantation, Virus
Papers published on a yearly basis
Papers
More filters
TL;DR: The pharmacological data further support the clinical evaluation of the utility of GLP-1R agonists for treatment of NASH and Interestingly, the role of endogenous GLp-1Rs in NASH merits further exploration as the GLP -1RKO model was protected from the deleterious hepatic effects of HTF.
Abstract: These preclinical studies aimed to 1) increase our understanding the dietary induction of nonalcoholic steatohepatitis (NASH), and, 2) further explore the utility and mechanisms of glucagon-like pe...
217 citations
TL;DR: In this article, a literature search resulted in 57 studies on the effectiveness of mindfulness meditation in reducing stress and anxiety in college students, including self-reported stress, selfreported stress in 34, physiological stress in 11, and mindfulness in 24.
216 citations
TL;DR: Twelve-week efalizumab treatment resulted in significant improvement; extension of therapy to 24 weeks resulted in additional improvement in patients who initially had not achieved PASI-75.
Abstract: Background Efalizumab inhibits multiple T-cell–mediated processes. Objective To evaluate 12- and 24-week efalizumab therapy for psoriasis. Methods In this phase III, randomized, double-blind trial, 498 patients received subcutaneous 1 or 2 mg/kg/wk efalizumab or placebo for 12 weeks. Efalizumab-treated patients who achieved Results At week 12, 39% and 27% of efalizumab-treated patients (1 and 2 mg/kg, respectively) achieved PASI-75 (vs 2% placebo; P P =.018). Efalizumab was well tolerated. Conclusion Twelve-week efalizumab treatment resulted in significant improvement; extension of therapy to 24 weeks resulted in additional improvement in patients who initially had not achieved PASI-75. There were no significant changes in safety profile during weeks 13-24.
216 citations
Virginia Commonwealth University1, National Institutes of Health2, University of California, Irvine3, University of Colorado Denver4, University of Southern California5, University of Michigan6, University of Connecticut7, Saint Louis University8, University of Texas Southwestern Medical Center9, Harvard University10, University of Washington11
TL;DR: Reducing the peginterferon dose during the first 20 weeks of treatment reduced viral clearance and SVR and Discontinuing ribavirin prematurely was associated with a marked decline in both VR and S VR.
216 citations
TL;DR: It is concluded that caloric restriction and exercise result in limited weight gain in obese subjects with GDM, less macrosomic neonates, and no adverse pregnancy outcomes.
Abstract: Objective: This study assessed whether a weight-gain restriction regimen, with or without exercise, would impact glycemic control, pregnancy outcome, and total pregnancy weight gain in obese subjec...
215 citations
Authors
Showing all 19076 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Douglas G. Altman | 253 | 1001 | 680344 |
| John E. Morley | 154 | 1377 | 97021 |
| Roberto Romero | 151 | 1516 | 108321 |
| Daniel S. Berman | 141 | 1363 | 86136 |
| Gregory J. Gores | 141 | 686 | 66269 |
| Thomas J. Smith | 140 | 1775 | 113919 |
| Richard T. Lee | 131 | 810 | 62164 |
| George K. Aghajanian | 121 | 277 | 48203 |
| Reza Malekzadeh | 118 | 900 | 139272 |
| Robert N. Weinreb | 117 | 1124 | 59101 |
| Leslee J. Shaw | 116 | 808 | 61598 |
| Thomas J. Ryan | 116 | 675 | 67462 |
| Josep M. Llovet | 116 | 399 | 83871 |
| Robert V. Farese | 115 | 473 | 48754 |
| Michael Horowitz | 112 | 982 | 46952 |